# US 8,278,344 B2 · Heterocyclic inhibitors of necroptosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,344 B2
- Document ID: US8278344B2
- Status: Granted
- Kind: B2
- Application number: 12/859,997
- Filed: 2010-08-20
- Published: 2010-12-16
- Granted: 2012-10-02
- Earliest claimed: 2007-08-15
- Assignees: The Brigham and Women's Hospital, Inc.; President and Fellows of Harvard College; Tufts University
- Inventors: Gregory D. Cuny; Xin Teng; Junying Yuan; Alexei Degterev
- Web page: https://patentgrep.com/patent/US8278344B2

## CPC

- C07D 417/12: linked by a chain containing hetero atoms as chain links
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/18: for HIV
- A61P 31/20: for DNA viruses
- A61P 31/22: for herpes viruses
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 207/34: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 231/14: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 241/24: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 263/34: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 277/56: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 285/06: 1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
- C07D 307/68: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 307/84: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 333/38: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-α) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I) and (Ia)-(Ie) and are shown to inhibit TNF-α induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring the compounds of the invention. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.

## Claims

### Claim 1

A method of treating necrosis or necroptosis in a subject having a condition selected from stroke, myocardial infarction, organ ischemia, traumatic brain injury, liver disease, cancer chemo/radiation therapy-induced necrosis, acute necrotizing pancreatitis, or a neurodegenerative disease, said method comprising the step of administering a compound according to the following formula,
wherein
R1 is a lower alkyl group;
R2 is selected from hydrogen and an electron withdrawing group;
R3 is selected from hydrogen and an (S)-lower alkyl group;
each of R4, R5, and R6 is independently selected from hydrogen, lower alkyl, halogen, amino, amido, alkoxy, and cyano; and
each X1 and X2 is, independently, halogen;
or any pharmaceutically acceptable salt thereof, or stereoisomer thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein said condition is a neurodegenerative disease.

### Claim 3 (depends on 1)

The method of claim 1, wherein said condition is stroke, liver disease, myocardial infarction, or retinal ischemia.

### Claim 4 (depends on 1)

The method of claim 1, wherein
R1 is selected from methyl, ethyl, propyl, and butyl;
R2 is selected from hydrogen, halogen and cyano; and
R3 is selected from hydrogen, (S)-methyl, (S)-ethyl, (S)-propyl, and (S)-butyl.

### Claim 5 (depends on 4)

The method of claim 4, wherein
R1 is selected from methyl and isopropyl;
R2 is selected from hydrogen, chlorine, bromine and cyano;
R3 is selected from hydrogen and (S)-methyl; and
each X1 and X2 is independently chlorine or fluorine.

### Claim 6 (depends on 5)

The method of claim 5, wherein R1 is methyl, R2 is cyano, R3 is (S)-methyl, X1 is chlorine, and X2 is fluorine.

### Claim 7

A method of treating necrosis or necroptosis in a subject having a condition selected from organ ischemia, traumatic brain injury, liver disease, cancer chemo/radiation therapy-induced necrosis, acute necrotizing pancreatitis, or a neurodegenerative disease, said method comprising the step of administering a compound selected from the group consisting of:
or any pharmaceutically acceptable salt thereof, or stereoisomer thereof,
to said subject in a dosage sufficient to decrease necroptosis or said necrosis.

### Claim 8 (depends on 7)

The method of claim 7, wherein said compound is
or any pharmaceutically acceptable salt thereof, or stereoisomer thereof.

### Claim 9 (depends on 7)

The method of claim 7, wherein said condition is a neurodegenerative disease.

### Claim 10 (depends on 7)

The method of claim 7, wherein said condition is stroke, liver disease, myocardial infarction, or retinal ischemia.
